dc.contributor.author | Yeung, P. K. | en_US |
dc.contributor.author | Ferguson, C. | en_US |
dc.contributor.author | Jarrar, A. | en_US |
dc.contributor.author | King, B. | en_US |
dc.contributor.author | Li, M. L. | en_US |
dc.date.accessioned | 2013-09-24T15:00:34Z | |
dc.date.available | 2013-09-24T15:00:34Z | |
dc.date.issued | 2007 | en_US |
dc.identifier.citation | Yeung, P. K., C. Ferguson, A. Jarrar, B. King, et al. 2007. "Development and validation of a sensitive and specific HPLC assay of cladribine for
pharmacokinetics studies in rats." Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian
Society for Pharmaceutical Sciences, Societe canadienne des sciences
pharmaceutiques 10(2): 231-236. | en_US |
dc.identifier.issn | 1482-1826 | en_US |
dc.identifier.uri | http://hdl.handle.net/10222/36665 | |
dc.description.abstract | PURPOSE: To develop and validate a sensitive and specific HPLC assay for cladribine
(CdA) in plasma for pharmacokinetic studies in rats. METHODS: CdA and the internal
standard AZT were purchased from Sigma-Aldrich Chem. The HPLC system consisted of a
Shimadzu LC-9A pump, a 3 im, 250 x 2.0 mm I.D. high speed C18 column (Jupitertrade
mark), preceded by a 5 im 4 4 mm I.D. C18 guard column (Licrocarttrade mark), an Agilent
Model 1050 UV-VIS detector and a 3395 Integrator. The mobile phase was made up of 0.01M
KH2PO4 (pH 5): methanol: acetonitrile 90:5:5). The system was operated at ambient
temperature with a flow rate of 0.3 mL/min, and UV wavelength at 265 nm, and an
operating pressure of ca. 1.56 kpsi. Extraction of cladribine and AZT from plasma was
achieved by solid phase extraction using 100 mg/mL C18 SPE columns Extra-septrade mark).
The assay was validated for sensitivity, precision, specificity and application for
pharmacokinetic study in rats. RESULTS: Under these conditions, the average retention
times of CdA and AZT were 13.5 and 21 min, respectively, and recoveries were between 80
- 95%. Standard curve constructed from plasma standards was linear from 0.1 ug/mL to 1
ug/mL with regression coefficient (r2) 0.99 or greater. Sensitivity assessed by on
column injection was < 1 ng. Using a 50-uL plasma sample size, the mean intra
assay variations 0.1 ug/mL were 7%, and inter assay variations over a period of 3 months
for 5 separate batches were less than 20%. The assay was used to study a single dose
pharmacokinetic study of CdA in rats after a 2 mg/kg subcutaneous injection. CONCLUSION:
The described HPLC assay has adequate sensitivity and specificity to study
pharmacokinetics of CdA in rats, and could be adapted also to clinical pharmacokinetic
studies. | en_US |
dc.language.iso | Check Language Code | en_US |
dc.relation.ispartof | Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian
Society for Pharmaceutical Sciences, Societe canadienne des sciences
pharmaceutiques | en_US |
dc.title | Development and validation of a sensitive and specific HPLC assay of cladribine for
pharmacokinetics studies in rats | en_US |
dc.type | Text | en_US |
dc.identifier.volume | 10 | en_US |
dc.identifier.issue | 2 | en_US |
dc.identifier.startpage | 231 | en_US |